Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
41.66
+0.18 (0.43%)
At close: Feb 17, 2026, 4:00 PM EST
41.50
-0.16 (-0.38%)
After-hours: Feb 17, 2026, 5:50 PM EST
Xenon Pharmaceuticals Revenue
Xenon Pharmaceuticals had revenue of $7.50M in the twelve months ending September 30, 2025.
Revenue (ttm)
$7.50M
Revenue Growth
n/a
P/S Ratio
429.24
Revenue / Employee
$22,936
Employees
327
Market Cap
3.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 9.43M | -9.00M | -48.83% |
| Dec 31, 2021 | 18.44M | -13.73M | -42.68% |
| Dec 31, 2020 | 32.17M | 25.34M | 371.02% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 909.05M |
| Catalyst Pharmaceuticals | 578.20M |
| Arcutis Biotherapeutics | 317.93M |
| Ligand Pharmaceuticals | 251.23M |
| Liquidia | 69.22M |
| Centessa Pharmaceuticals | 15.00M |
XENE News
- 4 weeks ago - Polarean Expands Xenon MRI Platform into Cardiopulmonary Drug Development with Multi-Center PH-ILD Study - GlobeNewsWire
- 4 weeks ago - Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Xenon Pharmaceuticals Inc. (XENE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout - Seeking Alpha
- 2 months ago - Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript - Seeking Alpha
- 2 months ago - Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 - GlobeNewsWire